Royalty Report: Drugs, Therapeutic, Disease – Collection: 7362


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 8


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8

Primary Industries

  • Drugs
  • Therapeutic
  • Disease
  • Pharmaceuticals
  • Multiple Sclerosis
  • Biotechnology
  • Proteins

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7362

License Grant
Pursuant to the Agreement, the Licensee has an option to acquire an exclusive, worldwide (excluding Japan) License of our Tcelna program for the treatment of MS.
License Property
The Licensor is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS). This therapy is based on proprietary T-cell technology. MS is a chronic, often disabling disease that affects the central nervous system. MS attacks the covering surrounding nerve cells, or myelin sheaths, leading to loss of myelin (demyelination) and nerve damage.

Tcelna is a novel T-cell immunotherapy in Phase IIb clinical development for the treatment of patients with SPMS. It is also positioned to enter Phase III clinical development for the treatment of patients with relapsing remitting MS (RRMS), subject to the availability of sufficient resources. Tcelna is a personalized therapy that is specifically tailored to each patient's disease profile. Tcelna is manufactured using ImmPathTM, our proprietary methodd for the production of a patient-specific T-cell immunotherapy which encompasses the collection of blood from the MS patient, isolation of peripheral blood mononuclear cells, generation of an autologous pool of MRTCs raised against selected peptides from myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), and the return of these expanded, irradiated T-cells back to the patient.

IPSCIO Record ID: 185511

License Grant
Licensee entered into an agreement with College for the exclusive worldwide license to a patient-specific, autologous T-cell immunotherapy for the treatment of MS, which is the initial T-cell technology on which Tcelna is based, including rights to certain patents held by the College.
License Property
Tcelna was based on our novel T-cell immunotherapy platform, ImmPath, which produces an autologous T-cell immunotherapy utilizing a patient’s own blood.
Field of Use
Tcelna® is a personalized T-cell immunotherapy in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis.

IPSCIO Record ID: 26620

License Grant
The Licensee has an exclusive, worldwide license from the College to develop and commercialize three technology areas for MS, namely T-cell vaccination, peptides, and diagnostics. Under the License Agreement with the College, the licensee will have rights to a total of 7 patents (2 U.S. and 5 foreign) and 69 patent applications (6 U.S., 62 foreign, and 1 Patent Cooperation Treaty [PCT]). Our multiple sclerosis cell therapy, Tovaxin, is currently in Phase I/II studies.
License Property
Tovaxin consists of modified auto reactive T cells. Multiple sclerosis is a result of a person’s own T cells attacking the myelin sheath that coats the nerve cells of the central nervous system. These T cells, that attack a person’s own body, are referred to as auto reactive T cells. In our treatment the T cells are taken from the patient, modified and returned to the patient. The modified T cells cause an immune response directed at the auto reactive T cells in the patient’s body. This immune response reduces the level of auto reactive T cells and potentially allows the myelin sheath to be repaired. In addition, we are evaluating whether this technology will allow us to diagnose multiple sclerosis and determine the severity of the disease through an analysis of the level of auto reactive T cells in a patient’s blood.

IPSCIO Record ID: 26724

License Grant
This License Agreement provides for worldwide distribution rights for so long as there are patent rights and the parties continue their corporate existence.
License Property
BOW 304 is a drug being developed for the treatment of Multiple Sclerosis and related neurological symptoms.  The product is to be developed through a joint development and marketing agreement with a British based research and development partnership.

Chronic progressive multiple sclerosis (MS) is a severely disabling demyelinating disease in which autoimmune processes seem to have a major role in the destruction of brain and nerve tissue. Treatment options are limited although beta-interferon has been widely reported to have some beneficial effect in MS. It is assumed that beta interferon has its action on the cells of the immune system that are attacking the patient’s nerve tissue.

Field of Use
The rights granted relate to neurological symptoms.

IPSCIO Record ID: 29049

License Grant
The Licensee was granted an exclusive, worldwide License from the College of Medicine, the Licensor, to patent applications claiming rights to the treatment of multiple sclerosis using attenuated modified T-cells and to the use of the T-cell technology as a diagnostic.
Field of Use
The Licensee is a biopharmaceutical company developing autologous cellular therapies to treat several major illnesses, including multiple sclerosis (MS), rheumatoid arthritis (RA), diabetes, and cardiovascular disease. These therapies are based on the Company’s proprietary T-cell and adult stem cell technology.

IPSCIO Record ID: 230784

License Grant
Licensor hereby grants to Canadian Licensee the exclusive worldwide right and license under the Patent Rights to use, manufacture, have manufactured, import, offer for sale and sell the Licensed Products for use in the Field.
License Property
The Licensor is a biopharmaceutical company that develops drug therapies for the treatment of inflammatory diseases.

USA Patents
6,039,947 – Peptides derived from immunodominant epitopes of myelin basic protein
5,858,980 – Peptide fragments of myelin basic protein
6,077,509 – Peptide fragments of myelin basic protein
6,036,957 – Suppression of T-cell proliferation using peptide fragments of myelin basic protein

Field of Use
Field shall mean the administration of native myelin basic protein (MBP) peptides by injection to non-mucosal sites for the treatment of multiple sclerosis.

IPSCIO Record ID: 237223

License Grant
Licensor grants to the Swiss Licensee an exclusive license with the right to sublicense, under the Licensor Technology to manufacture, have manufactured, develop, use, sell, import, and otherwise distribute Collaboration Products for use within the Licensee Territory and North America. Without limiting the foregoing, it is understood that the license granted hereunder shall extend to the use of Collaboration Products for multiple sclerosis as well as any other indication outside the Field.
License Property
Licensor Technology shall mean Licensor Patents and Licensor Know-How.  The Licensor discovers, develops and commercializes innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders.
Field of Use
The Parties desire to collaborate on the development and commercialization of altered peptide ligand compounds for the diagnosis, treatment and/or prevention of multiple sclerosis ('MS') in humans

Field shall mean the development, manufacture, use and sale of altered peptide ligand (APL) compounds for diagnosis, treatment and/or prevention of multiple sclerosis (MS) the mechanism of action of which is to modulate the immune response to neuro antigens, which neuro antigens include without limitation myelinoasic protein (which constitutes approximately 30% of the protein in myelin) as well as myelin associated glycoprotein (MAG), myelin oligodendroglia glycoprotein (MOG), transaldolase, 23 cyclic nuclcotide 3, phosphodieseterases (CNP), alpha/beta crystallin and proteolipid protein {PLP).

IPSCIO Record ID: 26212

License Grant
The Licensor grants to the Licensee the exclusive, worldwide right to conduct various technical, preclinical, marketing, patent, and other studies on products in the field of vaccines for the diagnosis or treatment of diseases.
License Property
Through our majority owned subsidiary Solovax we have an exclusive option agreement, as amended, with the University to license U.S. Patent Application serial nos. 09/156509 and 10/773356 and its foreign equivalents entitled “T-Cell Vaccination for the Treatment of Multiple Sclerosis.”
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.